Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply

JAMA Oncol. 2019 Dec 1;5(12):1806-1807. doi: 10.1001/jamaoncol.2019.4058.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Fluorouracil / adverse effects
  • Humans
  • Leucovorin / adverse effects
  • Liver Neoplasms* / drug therapy
  • Oxaliplatin / adverse effects
  • Portal Vein
  • Sorafenib

Substances

  • Oxaliplatin
  • Sorafenib
  • Leucovorin
  • Fluorouracil